NKX3.1 as a marker of prostatic origin in metastatic tumors.
about
High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate CancerConcurrent Down-Regulation of PTEN and NKX3.1 Expression in Iranian Patients with Prostate CancerMolecular genetics of prostate cancer: new prospects for old challengesThe effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.Expression changes in the stroma of prostate cancer predict subsequent relapseNKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples.Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges.Diagnostic and prognostic molecular biomarkers for prostate cancer.Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective.Biopsy sampling and histopathological markers for diagnosis of prostate cancer.Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.Comprehensive gene expression analysis reveals multiple signal pathways associated with prostate cancer.Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants.4C-seq revealed long-range interactions of a functional enhancer at the 8q24 prostate cancer risk locusSensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.Ligand-dependent enhancer activation regulated by topoisomerase-I activity.Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer?Histopathology of Prostate Cancer.Urine cytology of nonurothelial malignancies-a 10-year experience in a large multihospital healthcare system.Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.DNA methylation in promoter region as biomarkers in prostate cancer.MYC and Prostate CancerCribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.Mucinous and secondary tumors of the prostate.Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.Diagnostic challenges and problem cases in salivary gland cytology: A 20-year experience.Nephrogenic adenoma does not express NKX3.1.Characterization of kiss2 and kissr2 genes and the regulation of kisspeptin on the HPG axis in Cynoglossus semilaevis.A case of mucin-producing urothelial-type adenocarcinoma of the prostate showing immunoreactivity for NKX3.1, a specific marker of prostatic tissue.Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling.Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification.HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it!Chromatin Landscape Distinguishes the Genomic Loci of Hundreds of Androgen-Receptor-Associated LincRNAs From the Loci of Non-associated LincRNAs.HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin
P2860
Q26774902-FCBAF163-35DA-47E2-B410-5748B298B382Q28387281-438404EB-1B1A-45A3-B7E6-229C0848286FQ34127462-B045E594-348E-4D20-989C-A4734501A401Q34187693-6E8A3024-D726-40F5-AC34-B8C8FE28199AQ34368873-102EBFB4-117C-4260-ACC4-DEF5F558FE10Q35155656-06AEFB3D-318F-4EE4-AEC3-E80040034E53Q35665662-1EAB7A27-970A-4D82-9940-C419CB467BF8Q35772988-41D0B73F-3116-46BD-A184-2FF297AB6394Q35838821-1C3BF14C-3A80-4943-B550-CCFE2844EE0EQ37972703-D33C0289-0743-4ED4-9F77-025B28321A25Q38060845-10290E54-1ABC-4AA0-9C70-367ED24AD9D3Q38256309-3DC3E187-18BB-4AA1-AA06-88AD80CBA9CFQ38429979-F37ECED9-3D85-412B-8879-0A97E8EDF799Q38484180-4DF4BC25-B93D-4EBF-BCBD-01322FEB912BQ38676256-430A94FF-C133-4737-BA65-8F13D637B6DEQ38721818-2B2E2691-414F-45FB-A8C8-A4B89D413FACQ38744293-9E4C57C1-ACC6-453B-AD41-ACAE96685212Q38758020-4B0376D1-0867-439C-AE6F-C20CD225798EQ38916666-E4D5CB69-1A02-44C8-AE6A-A07E78B30942Q39117370-9B64DE40-96F1-4E92-A168-4F7012B68702Q39227648-330818ED-A936-4DC8-8946-8A6E8008A041Q39255544-382164EB-ABC2-4987-898F-9EEBBEFE14AEQ42184292-B77DEBA1-F796-4394-829A-D88A1562B7E3Q42261678-6623FF0E-EA7D-479F-80AE-7B1CFE29C85DQ42731671-06814F54-DF92-45A8-BB66-DDF197FEAAF3Q47158122-F9BE5ED5-D468-407B-99DB-22619016F61DQ47664729-B3C70A0A-28B4-4669-A891-7EBB117FF3EAQ48098802-D6A94F19-3809-40EF-9725-778707FEBBA7Q48315920-11CAF4DE-AA47-4917-A092-302CF8692139Q48329035-A77A8C27-66CF-482C-8F63-176E88B90636Q48340950-B8A6ACA4-B5E8-4714-83AC-713037FE5C87Q50227040-55D93A05-347B-472B-BF79-FCCA13246B95Q51320597-4D60BEA3-C669-4DBF-B2CF-73F586BF202AQ52629153-044C4477-CF7E-41B6-AE4B-F2D6A45CCC3AQ53159843-A6CED37A-2A0D-4FCA-BA18-A8D736727CC3Q53489177-523EE653-DC28-4419-AF8D-773CADA3379CQ54983326-BE60B407-08A8-4C0A-B0FC-B852C42183DEQ55059437-259CF0B5-DDBF-430B-A494-41B99DD4B214Q57565094-511B74E4-E94F-479A-AA72-EC272911B67F
P2860
NKX3.1 as a marker of prostatic origin in metastatic tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
NKX3.1 as a marker of prostatic origin in metastatic tumors.
@ast
NKX3.1 as a marker of prostatic origin in metastatic tumors.
@en
NKX3.1 as a marker of prostatic origin in metastatic tumors.
@nl
type
label
NKX3.1 as a marker of prostatic origin in metastatic tumors.
@ast
NKX3.1 as a marker of prostatic origin in metastatic tumors.
@en
NKX3.1 as a marker of prostatic origin in metastatic tumors.
@nl
prefLabel
NKX3.1 as a marker of prostatic origin in metastatic tumors.
@ast
NKX3.1 as a marker of prostatic origin in metastatic tumors.
@en
NKX3.1 as a marker of prostatic origin in metastatic tumors.
@nl
P2093
P2860
P50
P1476
NKX3.1 as a marker of prostatic origin in metastatic tumors
@en
P2093
Angelo M De Marzo
Douglas P Clark
Elizabeth A Montgomery
Jessica Hicks
Jonathan I Epstein
Shahnaz Begum
Tehmina Z Ali
P2860
P304
P356
10.1097/PAS.0B013E3181E6CBF3
P407
P577
2010-08-01T00:00:00Z